$33.85
2.08% day before yesterday
Nasdaq, Jan 02, 10:02 pm CET
ISIN
US45166A1025
Symbol
IDYA

IDEAYA Biosciences Inc Stock price

$33.85
+0.16 0.47% 1M
+11.93 54.43% 6M
-0.72 2.08% YTD
+8.69 34.54% 1Y
+15.68 86.30% 3Y
+20.36 150.93% 5Y
+22.66 202.50% 10Y
+22.66 202.50% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.72 2.08%
ISIN
US45166A1025
Symbol
IDYA
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.2b
Net debt
positive
Cash
$786.9m
Shares outstanding
87.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.8 | 15.3
EV/Sales
10.2 | 11.3
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
94.2%
Return on Equity
-25.9%
ROCE
-18.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$214.8m | $193.4m
EBITDA
$-206.5m | $-159.0m
EBIT
$-209.1m | $-184.2m
Net Income
$-160.3m | $-125.0m
Free Cash Flow
$-105.4m
Growth (TTM | estimate)
Revenue
5,380.4% | 2,662.9%
EBITDA
7.1% | 51.0%
EBIT
7.0% | 43.7%
Net Income
10.1% | 54.5%
Free Cash Flow
31.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-96.1% | -82.2%
EBIT
-97.3%
Net
-74.6% | -64.6%
Free Cash Flow
-49.1%
More
EPS
$-1.8
FCF per Share
$-1.2
Short interest
9.7%
Employees
131
Rev per Employee
$50.0k
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a IDEAYA Biosciences Inc forecast:

22x Buy
88%
3x Hold
12%

Analyst Opinions

25 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
88%
Hold
12%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
215 215
5,380% 5,380%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
59% 59%
26%
- Research and Development Expense 294 294
52% 52%
137%
-207 -207
7% 7%
-96%
- Depreciation and Amortization 2.55 2.55
5% 5%
1%
EBIT (Operating Income) EBIT -209 -209
7% 7%
-97%
Net Profit -160 -160
10% 10%
-75%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
PRNewsWire
23 days ago
Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United States SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, t...
Neutral
PRNewsWire
24 days ago
Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026 Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026 SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, annou...
Neutral
Business Wire
29 days ago
BEIJING--(BUSINESS WIRE)-- #Biocytogen--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a ...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 131
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today